OneSource Specialty Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• OneSource Specialty Pharma Ltd reported a 45.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.3%.
• Its expenses for the quarter were up by 13.1% QoQ and 24.7% YoY.
• The net profit decreased 105.2% QoQ and decreased 95.3% YoY.
• The earnings per share (EPS) of OneSource Specialty Pharma Ltd stood at 0.4 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

OneSource Specialty Pharma Ltd is a company operating within the pharmaceutical industry, focusing on the development and commercialization of specialty pharmaceutical products. The company is known for its research-driven approach to creating innovative solutions tailored to specific medical needs. However, specific details about its main products or services, as well as any recent major developments, are not available in the provided data. It is important for stakeholders to have a detailed understanding of the company's offerings and strategic initiatives to assess its market position and future potential.

Revenue

In Q4FY26, OneSource Specialty Pharma Ltd reported a total income of ₹430.31 crores, marking a significant quarter-over-quarter (QoQ) increase of 45.9% compared to ₹294.96 crores in Q3FY26. This robust growth could be indicative of a positive shift in sales or market conditions during this period. On a year-over-year (YoY) basis, the total income saw a modest increase of 0.3% from ₹428.84 crores in Q4FY25. This data highlights the company’s ability to maintain a stable revenue stream over the past year, despite fluctuations in quarterly performance.

Profitability

The profitability metrics for OneSource Specialty Pharma Ltd in Q4FY26 show a complex picture. The company posted a Profit After Tax (PAT) of ₹4.60 crores, a notable recovery from a loss of ₹88.70 crores in Q3FY26. This represents a considerable QoQ turnaround of 105.2%. However, when compared to Q4FY25, where the PAT was ₹98.50 crores, there is a significant YoY decline of 95.3%. The Profit Before Tax (PBT) for Q4FY26 was nearly breakeven at -₹0.29 crores. The Earnings Per Share (EPS) followed a similar trend, showing a QoQ recovery to ₹0.40 from -₹7.74, but a YoY decrease from ₹8.59.

Operating Metrics

The operating metrics reveal an increase in total expenses, which amounted to ₹430.64 crores in Q4FY26. This reflects a 13.1% QoQ increase from ₹380.89 crores in Q3FY26 and a 24.7% YoY increase from ₹345.34 crores in Q4FY25. The substantial rise in expenses could be attributed to higher operational costs or strategic investments. Tax expenses in Q4FY26 were -₹4.89 crores, which represents a QoQ increase of 13.5% from -₹4.31 crores in Q3FY26 and a YoY decrease of 68.8% from -₹15.69 crores in Q4FY25. These figures suggest fluctuations in tax obligations, possibly reflecting changes in taxable income or adjustments in tax strategy.